Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and …

hiv test
programmed cell death 1 ligand 1
stage iv non-small cell lung cancer
carcinoma
docetaxel
  • 0 views
  • 19 Feb, 2024
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: To determine the effect of venglustat on the …

autosomal dominant
renal function
ophthalmological examination
tolvaptan
treatment regimen
  • 0 views
  • 19 Feb, 2024
  • 81 locations
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

small cell lung cancer
curative surgery
measurable disease
stage iv non-small cell lung cancer
lung adenocarcinoma
  • 0 views
  • 19 Feb, 2024
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer

This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB/IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.

hiv test
carcinoma
egfr gene
pd-l1
hepatitis c antibody
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

  • 0 views
  • 19 Feb, 2024
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced NSCLC, but its application in neoadjuvant setting has not been well established. Results from a pilot clinical study reported the safety and feasibility of neoadjuvant PD-1 blockade. There are several neoadjuvant immunotherapy (NEOSTAR, LCMC3, NADIM, …

camrelizumab
anticoagulation therapy
endobronchial ultrasound
blood transfusion
cancer immunotherapy
  • 0 views
  • 19 Feb, 2024
Study of Poziotinib in Japanese Patients With NSCLC

A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).

small cell lung cancer
systemic therapy
metastasis
kidney function test
stage iv non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent chemoradiotherapy(CCRT) combined with nimotuzumab can improve the survival rate of high-risk patients and may provide new evidence for individualized comprehensive treatment of …

chemoradiotherapy
renal function test
egfr blocker
cancer
carcinoma
  • 4 views
  • 19 Feb, 2024
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction chemotheray(IC), determining whether radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence for individualized comprehensive treatment of …

cisplatin
renal function test
egfr blocker
cancer
carcinoma
  • 0 views
  • 19 Feb, 2024
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e.

  • 0 views
  • 19 Feb, 2024